

March 6, 2024

**To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort, Mumbai – 400 001**

**To,  
The Manager – Listing  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051**

**Ref: Scrip Code: 532296**

**Ref: Scrip Name: GLENMARK**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30(7) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We refer to our letter dated September 21, 2023 in relation to the sale of 91,895,379 equity shares (“**Sale Shares**”) representing 75.00% of the issued and paid-up equity share capital of Glenmark Life Sciences Limited (“**GLS**”), a subsidiary of the Company, to Nirma Limited (the “**Buyer**”) in accordance with the terms of the share purchase agreement dated September 21, 2023 among the Company, GLS and the Buyer (the “**Share Purchase Agreement**”).

Closing under the Share Purchase Agreement has been initiated; 67,389,944 equity shares representing 55% of the issued and paid-up equity share capital of GLS have been transferred by the Company to the Buyer; and closing will be complete upon the completion of the transfer of the remaining Sale Shares.

This is for your information and records. Request you to please ignore the earlier letter.

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Harish Kuber  
Company Secretary & Compliance Officer**

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)